TipRanks on MSN
Eli Lilly’s retatrutide study: A new hope for CKD treatment?
Eli Lilly And Company ($LLY) announced an update on their ongoing clinical study. Study Overview: Eli Lilly and Company ...
Analysts were hoping for a safety profile similar to what was achieved in Phase II but an abnormal sense of touch, called ...
In an added benefit, more than one in eight people taking the highest dose of Retratrutide were completely free of arthritic ...
Eli Lilly has surpassed analysts’ highest hopes for the efficacy of retatrutide, linking the triple agonist to 28.7% weight ...
Can anything stop this high-flying drugmaker?
StockStory.org on MSN
Eli Lilly (LLY) Stock Is Up, What You Need To Know
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.4% in the morning session after the company announced ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback